Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial

被引：27
|
作者：
Spaner, David E. [1 ,2 ,3 ,4 ,5 ]
Wang, Guizhei [1 ]
McCaw, Lindsay [1 ]
Li, Yanmei [1 ]
Disperati, Patricia [6 ]
Cussen, Mary-Ann [3 ]
Shi, Yonghong [1 ]
机构：
[1] Sunnybrook Res Inst, Biol Platform, Toronto, ON, Canada
[2] Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A1, Canada
[3] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[4] Univ Toronto, Dept Med, Toronto, ON M5S 1A1, Canada
[5] Univ Toronto, Dept Immunol, Toronto, ON M5S 1A1, Canada
[6] Toronto East Gen Hosp, Toronto, ON, Canada
来源：
HAEMATOLOGICA | 2016年 / 101卷 / 05期
关键词：
chronic lymphocytic leukemia; Janus Kinases; STAT3; Ruxolitinib; Ibrutinib; Kinase inhibitors; phosphoproteome; FOLLOW-UP; RESISTANCE; THERAPY; CELLS; CLL;
D O I：
10.3324/haematol.2015.135418
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia
    Padron, Eric
    DeZern, Amy E.
    Niyongere, Sandrine
    Ball, Markus Christian
    Balasis, Maria
    Ramadan, Hanadi
    Lancet, Jeffrey E.
    List, Alan F.
    Mesa, Ruben A.
    Roboz, Gail J.
    Steensma, David P.
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    BLOOD, 2017, 130
  • [22] Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study
    Byrd, J. C.
    Blum, K. A.
    Burger, J. A.
    Coutre, S. E.
    Sharman, J. P.
    Furman, R. R.
    Flinn, I. W.
    Grant, B. W.
    Richards, D. A.
    Zhao, W.
    Heerema, N. A.
    Johnson, A. J.
    Izumi, R.
    Hamdy, A.
    O'Brien, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia
    Pleyer, Christopher
    Wiestner, Adrian
    Sun, Clare
    LEUKEMIA & LYMPHOMA, 2018, 59 (12) : 2792 - 2800
  • [24] Anterior Uveitis After Discontinuation of Janus Kinase Inhibitor, Ruxolitinib
    Matsuo, Toshihiko
    Ikeda, Naoto
    Monobe, Yasumasa
    Tanaka, Takehiro
    JOURNAL OF MEDICAL CASES, 2024, 15 (08) : 208 - 214
  • [25] Remission of food allergy by the Janus kinase inhibitor ruxolitinib in mice
    Yamaki, Kouya
    Yoshino, Shin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2014, 18 (02) : 217 - 224
  • [26] Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor
    Sanford, David
    Kantarjian, Hagop
    Skinner, Jeffrey
    Jabbour, Elias
    Cortes, Jorge
    HAEMATOLOGICA, 2015, 100 (12) : E494 - E495
  • [27] A Pilot Phase II Study of the Lyn Kinase Inhibitor Bafetinib in Patients with Relapsed or Refractory B Cell Chronic Lymphocytic Leukemia
    Kadia, Tapan
    Delioukina, Maria L.
    Kantarjian, Hagop M.
    Keating, Michael J.
    Wierda, William G.
    Burger, Jan A.
    Wieland, Scott
    Levitt, Daniel
    BLOOD, 2011, 118 (21) : 1232 - 1233
  • [28] Phase II Trial of Pulse Dosed Lenalidomide In Previously Treated Chronic Lymphocytic Leukemia
    Aue, Georg
    Soto, Susan
    Valdez, Janet
    Arthur, Diane C.
    Tian, Xin
    Wiestner, Adrian
    BLOOD, 2010, 116 (21) : 595 - 595
  • [29] Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia
    Chavez, Julio C.
    Piris-Villaespesa, Miguel
    Dalia, Samir
    Powers, John
    Turba, Elyce
    Nodzon, Lisa
    Komrokji, Rami
    Sokol, Lubomir
    Locke, Frederick L.
    Lancet, Jeffrey
    Sotomayor, Eduardo M.
    Kharfan-Dabaja, Mohamed A.
    Pinilla-Ibarz, Javier
    LEUKEMIA RESEARCH, 2016, 47 : 78 - 83
  • [30] Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia
    Wolska-Washer, Anna
    Robak, Tadeusz
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (03) : 183 - 194
12345